clinical trial · NCT04003857
Follow-up Study of Safety and Efficacy in Subjects Who Completed PNEUMOSTEM® Phase II (MP-CR-012) Clinical Trial
Bronchopulmonary DysplasiaBPDPNEUMOSTEM®normal saline
brief summary
This is a follow-up study to investigate the long-term safety and efficacy of PNEUMOSTEM® versus placebo, for the treatment of BPD in premature infants. Subjects who participated in and completed the initial stage of the Phase II trial (NCT03392467) will be followed-up until 60 months of corrected age
started
Jul 5, 2019
primary completion
Jun 30, 2027
completion
Jun 30, 2027
last updated
Feb 7, 2025
detailed description
Subjects who completed the initial stage of the Phase II clinical trial will be followed-up at 7 additional visits: 6, 12,18, 24 months corrected age, 36, 48, and 60 months after birth.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol